Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 15/20 | 0.45 |
| ▸ | CYP11B1 | P15538 | 11/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | XDH | P47989 | 1/20 | 0.41 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.41 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17806342 | 0.85 | CYP11B2 (0.43) | CYP11B2CYP11B1CYP19A1CYP3A4XDH | |
| SCHEMBL17809667 | 0.85 | KDM4E (0.41) | CYP11B2CYP11B1ALDH1A1TSHRHSD17B10 | |
| SCHEMBL17809650 | 0.85 | ALDH1A1 (0.41) | CYP11B2CYP11B1ALDH1A1HSD17B10 | |
| SCHEMBL17809654 | 0.83 | CYP11B2 (0.41) | CYP11B2CYP11B1ALDH1A1HSD17B10XDH | |
| SCHEMBL17809647 | 0.82 | CYP11B2 (0.40) | CYP11B2CYP11B1ALDH1A1HSD17B10 | |
| SCHEMBL17809673 | 0.81 | CYP11B2 (0.41) | CYP11B2CYP11B1ALDH1A1HSD17B10 | |
| SCHEMBL17809787 | 0.81 | CYP11B2 (0.41) | CYP11B2CYP11B1ALDH1A1HSD17B10 | |
| SCHEMBL17794997 | 0.81 | CYP11B2 (0.39) | CYP11B2CYP11B1ALDH1A1TSHRHSD17B10 | |
| SCHEMBL17809629 | 0.79 | USP30 (0.53) | ALDH1A1HSD17B10 | |
| SCHEMBL17809652 | 0.79 | LRRK2 (0.40) | CYP11B2CYP11B1CYP3A4ALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3224258-B1 | 4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[4,3-C]PYRIDIN-3-AMINE COMPOUNDS AS CBP AND/OR EP300 INHIBITORS | GENENTECH INC (US) | 2019-08-14 | — | — | EP | disclosed |
| US-20170333406-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-23 | — | — | US | disclosed |
| US-9763922-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2017-09-19 | — | — | US | disclosed |
| US-20160158207-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170333406-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | EP300, HDAC1, HDAC10 | CYP11B2 1605/4885CYP11B1 1468/4885CYP19A1 3059/4885 |
| US-20160158207-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | EP300, HDAC1, HDAC10 | CYP11B2 1605/4885CYP11B1 1468/4885CYP19A1 3059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.